BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23679874)

  • 1. Molecularly targeted therapies for nonmelanoma skin cancers.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 Jun; 52(6):654-65. PubMed ID: 23679874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer.
    O'Bryan KW; Ratner D
    Semin Cutan Med Surg; 2011 Mar; 30(1):57-61. PubMed ID: 21540021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib.
    Iarrobino A; Messina JL; Kudchadkar R; Sondak VK
    J Am Acad Dermatol; 2013 Jul; 69(1):e33-4. PubMed ID: 23768306
    [No Abstract]   [Full Text] [Related]  

  • 4. [Molecular target therapies for skin cancers].
    Uhara H
    Nihon Rinsho; 2015 Aug; 73(8):1391-7. PubMed ID: 26281695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing pathology with changing drugs: skin cancer.
    Karpova MB; Barysch MJ; Zipser MC; Schönewolf N; French LE; Dummer R
    Pathobiology; 2011; 78(2):61-75. PubMed ID: 21677470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic treatment options for advanced epithelial skin cancer.
    Soura E; Chasapi V; Stratigos AJ
    Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma.
    Orouji A; Goerdt S; Utikal J; Leverkus M
    Br J Dermatol; 2014 Aug; 171(2):431-3. PubMed ID: 24446722
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not".
    Volkow P; Zinser JW; Correa-Rotter R
    BMC Nephrol; 2007 Mar; 8():6. PubMed ID: 17386117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

  • 10. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
    Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
    Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST
    J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
    Ali FR; Lear JT
    Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vismodegib in metastasized basal cell carcinoma].
    Reinders MG; Dirix L; Mosterd K; van Doorn R
    Ned Tijdschr Geneeskd; 2013; 157(12):A6011. PubMed ID: 23515044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.
    Mohan SV; Chang J; Li S; Henry AS; Wood DJ; Chang AL
    JAMA Dermatol; 2016 May; 152(5):527-32. PubMed ID: 26914338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor.
    Sawyers CL
    J Clin Oncol; 2002 Sep; 20(17):3568-9. PubMed ID: 12202652
    [No Abstract]   [Full Text] [Related]  

  • 16. Update of cetuximab for non-melanoma skin cancer.
    Wollina U
    Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib, a hedgehog pathway inhibitor for adults with locally advanced or metastatic basal cell carcinoma.
    Wilkes GM
    Oncology (Williston Park); 2012 Aug; 26(8 Suppl Nurse Ed):31-3. PubMed ID: 25375009
    [No Abstract]   [Full Text] [Related]  

  • 18. Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.
    Prescrire Int; 2015 Jan; 24(156):11-4. PubMed ID: 25729822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage.
    Zhu GA; Sundram U; Chang AL
    JAMA Dermatol; 2014 Sep; 150(9):970-3. PubMed ID: 24740281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.